Percutaneous sclerotherapy for venous malformations in the extremities: clinical outcomes and predictors of patient satisfaction

SpringerPlus

Table 1 Patient demographics and clinical data

Variables	n = 40
Age^a	28.2(11–69)
Sex (male:female)	11:29
Location of VM^b
Upper extremity	16(40)
Lower extremity	24(60)
Previous treatment^b
Operation	11(28)
with sclerotherapy	2(5)
with TAE	1(3)
Number of sclerotherapy treatments^a	2.6(1–10)
Sclerosants (partially overlapped)^b
Polidocanol	37(93)
Absolute ethanol	11(28)
Ethanolamine oleate	6(15)
Dose of sclerosants (ml)/session^a
Polidocanol	2.8(0.4-7.0)
Absolute ethanol	7.4(4.0-13)
Ethanolamine oleate	11.1(4.5-20)